Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer
Open Access
- 16 November 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (7), 1997-2010
- https://doi.org/10.1158/1078-0432.ccr-20-3322
Abstract
Nucleotide excision repair (NER) gene alterations constitute potential cancer therapeutic targets. We explored the prevalence of NER gene alterations across cancers and putative therapeutic strategies targeting these vulnerabilities. We interrogated our institutional dataset with mutational data from more than 40,000 patients with cancer to assess the frequency of putative deleterious alterations in four key NER genes. Gene-edited isogenic pairs of wild-type and mutant ERCC2 or ERCC3 cell lines were created and used to assess response to several candidate drugs. We found that putative damaging germline and somatic alterations in NER genes were present with frequencies up to 10% across multiple cancer types. Both in vitro and in vivo studies showed significantly enhanced sensitivity to the sesquiterpene irofulven in cells harboring specific clinically observed heterozygous mutations in ERCC2 or ERCC3. Sensitivity of NER mutants to irofulven was greater than to a current standard-of-care agent, cisplatin. Hypomorphic ERCC2/3-mutant cells had impaired ability to repair irofulven-induced DNA damage. Transcriptomic profiling of tumor tissues suggested codependencies between DNA repair pathways, indicating a potential benefit of combination therapies, which were confirmed by in vitro studies. These findings provide novel insights into a synthetic lethal relationship between clinically observed NER gene deficiencies and sensitivity to irofulven and its potential synergistic combination with other drugs. See related commentary by Jiang and Greenberg, p. 1833Keywords
Other Versions
Funding Information
- NIH NCI (P30 CA008748)
- The V Foundation for Cancer Research (P50 CA221745)
This publication has 53 references indexed in Scilit:
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Germline BRCA1 mutations increase prostate cancer riskBritish Journal of Cancer, 2012
- BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patientsBritish Journal of Cancer, 2011
- Predicting the functional impact of protein mutations: application to cancer genomicsNucleic Acids Research, 2011
- Molecular signatures database (MSigDB) 3.0Bioinformatics, 2011
- XPB, a subunit of TFIIH, is a target of the natural product triptolideNature Chemical Biology, 2011
- Calculation of Risk of Colorectal and Endometrial Cancer Among Patients With Lynch SyndromeGastroenterology, 2009
- Polymorphisms in DNA Repair Genes, Smoking, and Bladder Cancer Risk: Findings from the International Consortium of Bladder CancerCancer Research, 2009
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- Identification of the breast cancer susceptibility gene BRCA2Nature, 1995